News / Blogs

2023

• Started developing monoclonal antibodies to oncoprotein k-ras and k-ras mutant.

2022

• Developed Taup212p217 monoclonal antibodies for Alzheimer’s Disease research.

2021

• Started to develop CA19-9 antibodies using SW1116 cells as immunogen. Studied the stability of TNF alpha antibody and IL-17A antibody in different cosmetic bases for developing skin care products.

2020

• Developed more monoclonal antibodies to IL-6, IL-2 and IFN-g.

2019

• Developed monoclonal antibodies to Leukemia Inhibitory Factor (LIF). Started antibody production from cell culture supernatant. Developed more monoclonal antibodies to C-reactive protein (CRP).

2018

• Anogen’s IL-17A monoclonal antibodies, clone 10F9 and clone 2D11, have been shown to neutralize IL-17A induced IL-6 expression in human dermal fibroblasts. The IC50 was < 0.25mg/ml.

2017

• In a recent study with Alzheimer's disease animal model (APP/PS1 double transgenic mice), Anogen anti- amyloid peptide N-terminus antibody clone 3F5 reduced plaque on brain and improved cognition.

2016

• In a recent study with Alzheimer's disease animal model (APP/PS1 double transgenic mice), Anogen anti- amyloid peptide N-terminus antibody clone 3F5 reduced plaque on brain and improved cognition.

• Developed antibodies against primary tumor cells of triple negative breast cancer.

2015

• Participated in the laboratory medicine and pathology (LMP) vendor show in University of Toronto.

• Developed amyloid beta 42 peptide ELISA kit. Completed evaluation of anti-amyloid peptide antibodies with transgenic Alzheimer's disease mouse model.

2014

• Launched an upgraded website: www.anogen.net

2013

• Line of Mouse ELISA Kits released.

2012

• Started developing animal cytokine and chemokine products. New ELISA Kit products for mouse cytokine and receptors have been released.

• Set up a Facebook page and storefront.

• Released new Interleukin-6 (IL-6) anti-human antibodies and Tau Protein (Thr181 Phosphorylated) anti-human and mouse antibodies. They can be found in our monoclonal antibody listings.

2011

• Alpha 1-Antitrypsin and Alpha-Synuclein anti-human antibodies released.

• Interleukin-13 (IL-13) ELISA kit released.

• Beta amyloid peptide N-terminal and 40 anti-human antibodies released.

• Multiplex ELISA kit for simultaneous quantitative determination of pro-inflammatory cytokines released.

• Started preparing a new facility in Orlando, FL, USA.

2010

• Monoclonal antibodies for Interleukin-2, H.pylori(HP) cytotokine associated gene A protein (CagA) and M. tuberculosis (TB) 38Kd antigen released.

• “Humanized monoclonal antibody against the chemokine CXCL-8 (IL-8) effectively prevents acute lung injury” published in International Immunopharmacology.

2009

• Received Certificate of Recognition from the City of Mississauga on Anogen's 20th Anniversary.

• Developed panels of monoclonal antibodies to Alzheimer’s disease.

2008

• Introduced Beta-2 Microglobulin matched antibody pair, Beta-2 Microglobulin and p24 ELISA kits.

• Polyclonal antibodies for FPRL-1 and PML and a line of new phosphorylated monoclonal antibodies for CREB [p-S133], ELK-1 [pS383], and STAT5b [p-T694] released.

2007

• Introduced Beta-2 Microglobulin matched antibody pair, Beta-2 Microglobulin and p24 ELISA kits.

• Polyclonal antibodies for FPRL-1 and PML and a line of new phosphorylated monoclonal antibodies for CREB [p-S133], ELK-1 [pS383], and STAT5b [p-T694] released.

2007

• New lung carcinoma, free PSA, CEA, AFP, NSE and CA-125 antibodies released.

• Free PSA and AFP ELISA kits released.

2006

• Anogen introduced our new line of ELISPot kits.

• US patent “Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8” granted.

2005

• US patent “Monoclonal Antibodies Recognizing Human Platelet Membrane Glycoproteins And Use Thereof In Anti-Thrombotic Therapy” granted.

2004

• Anti-human platelet GPIIb/IIIa chimeric antibody completed pre-clinical studies.

2003

• Certified ISO 13485:03 Medical Devices under the general practice of the ISO 9001 Quality System.

• Humanized monoclonal antibodies to human platelet GPIIb/IIIa, to human IL-8 and to human MCP-1 developed for therapeutics.

2002

• Anti-IL8 neutralizing antibody cream (Abcream), developed for topical treatment of psoriasis and eczema, completed clinical trials in China.

2001

• Received patents from Australia, Canadian, China, and EU for "Topical Treatment Of Psoriasis Using Neutralizing Antibodies To Interleukin-8".

1998

• Developed a proprietary technology for topical antibody treatment of various skin conditions, representing a new area of antibody therapy.

1993

• Monoclonal antibodies to human serum amyloid A (SAA) and SAA ELISA Kit developed.

• Development of revolutionary anti-chemokine topical therapy for skin conditions started.

1992

• Developed panels of monoclonal antibodies to Chemokines MCP-1 and MCP-3 and ELISA Kits.

• Received grant from National Research Council (NRC) Canada Biotechnology Contribution Program on the “Development Of A Specific & Sensitive Assay For Blood-Borne Non-A, Non-B Hepatitis Virus”.

1991

• Developed panel of monoclonal antibodies to Chemokines Interleukin-8 (IL-8) and IL-8 ELISA kit.

1990

• Developed panels of monoclonal antibodies to Hepatitis C and HIV viruses.

1989

• Anogen-Yes Biotech Laboratories Ltd. was registered at Mississauga, Ontario, Canada.